IDWeek 2018
Biktarvy Demonstrates High Efficacy, Tolerability Through 96 Weeks
Gilead reported 96 week results for a comparative trial of Biktarvy in HIV patients who were treatment naive.
OCTOBER 9, 2018
Switching to Symtuza for HIV Maintains High Virologic Suppression Without Drug Resistance
Adults with HIV who are virologically suppressed maintained that suppression and low virologic failure after ...
OCTOBER 5, 2018
Load more